Differentiated Thyroid Cancer research hub
4 indexed studies · 1 currently recruiting
- active not recruitingPHASE3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
This study compares a new drug, cabozantinib, with a dummy drug (placebo) for differentiated thyroid cancer that has continued to grow despite previous treatments. It aims to see if cabozantinib can slow down the cancer's progression.
United States · Argentina · Australia - completedPhase II/III
ION - Is ablative radiOiodine Necessary for low risk differentiated thyroid cancer patients?
The ION trial tests whether people with low-risk thyroid cancer really need radioactive iodine after surgery. Usually, patients take radioactive iodine to destroy any remaining thyroid cells. This study compares surgery and daily hormone tablets alone against surgery with radioactive iodine, to see if extra radiation is truly necessary.
United Kingdom · England - recruitingNA
Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers
This study looks at whether removing part of the thyroid, instead of all of it, is a good and safe option for people with low-risk thyroid cancer. It aims to see if less surgery is just as effective and more cost-effective.
United Kingdom - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium